Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2004-04-29 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Reports First Quarter 2004 Results
Earnings Release Classification · 100% confidence The document is titled 'MorphoSys Reports First Quarter 2004 Results' and provides detailed financial figures (Revenues, operating expenses, profit, EBITDA, cash position) specifically for the first quarter ended March 31, 2004. This content structure—a press release summarizing key financial metrics for a specific interim period—aligns perfectly with the definition of an Earnings Release (ER). Although it contains some operational highlights, its primary function is the announcement of quarterly financial performance. Q1 2004
2004-04-29 English
Q1 Report 2004
Interim / Quarterly Report
2004-04-29 English
Q1 Bericht 2004
Interim / Quarterly Report
2004-04-29 German
MorphoSys Widens Scope of U.S. Patent for HuCAL(R) Technology
Regulatory Filings Classification · 100% confidence The document is a corporate news announcement dated April 19, 2004, detailing the granting of a new U.S. patent (US 6,706,484) that extends protection for MorphoSys's HuCAL(R) technology. This type of announcement, which reports on intellectual property developments, legal/patent news, or general corporate updates that do not fit into standard financial reporting categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR) if the focus was on litigation. Since this is a patent grant announcement, which is a form of regulatory/official notification but not a core financial report, RNS serves as the most appropriate general regulatory fallback category for non-standard corporate news releases. The document length is moderate (4915 chars), but its content is purely informational news, not a formal financial statement or a proxy solicitation.
2004-04-19 English
MorphoSys Achieves Fourth Milestone in Collaboration with Centocor
Regulatory Filings Classification · 95% confidence The document is a short corporate news announcement dated April 15, 2004, detailing the achievement of a milestone in a collaboration between MorphoSys and Centocor, which triggered a payment. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). It is a specific business update regarding a partnership milestone. Since there is no specific category for 'Collaboration Update' or 'Business Milestone Announcement', and it is not a transcript (CT), presentation (IP), or governance document (CGR/DEF 14A), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a general corporate news announcement sent via DGAP that doesn't fit the highly specific financial reporting codes.
2004-04-15 English
Q1 Report 2003
Interim / Quarterly Report
2004-03-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.